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Objective  To investigate the eff  ect of botulinum toxin type A (BTXA) on drooling and the morphologic change of 
the salivary gland in patients with cerebral palsy. 
Method  Eight cerebral palsy patients suff  ering from severe drooling participated in this study. BTXA was injected 
into both submandibular and parotid glands under intravenous sedation and with ultrasound guidance (1 unit/
gland/kg: maximum 100 units) in an outpatient or inpatient procedure. Th   e severity of drooling was measured 
before injection and 3 weeks after injection using the Teacher Drooling Scale, the Drooling Score-severity, 
frequency and the Visual Analog Scale. To investigate the morphologic change of the salivary glands, the size of 
salivary glands were measured before injection and 3 weeks after injection using computed tomography of the 
neck. Th   e measurement values were analyzed by Wilcoxon signed rank test. 
Results  Statistically significant improvements were shown in all three parameters for assessing the severity of 
drooling after BTXA injections (p<0.05). Size of the salivary glands were signifi  cantly decreased at 3 weeks after 
BTXA injection (p<0.05).
Conclusion  Salivary gland injection with BTXA could be a useful treatment method to reduce drooling in patients 
with cerebral palsy and decreased size of salivary glands may partially explain the mechanism.
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INTRODUCTION
  Drooling is the unintentional loss of saliva from the 
mouth due to immature or damaged oral motor skills. 
It occurs more frequently and severely in patients with 
neurological defi  cits such as cerebral palsy, motor neuron 
disease or Parkinson’s disease.
1,2 Persistent drooling 
may cause adverse events such as problems in social 
development and dignity of patients, as well as hygiene 
problems including unpleasant odor, contaminated 
clothing and furniture, and skin damage by repeated 
stimulation.
3,4 Additionally, in patients with brain injury Eﬀ  ect of BTXA on  Morphology of Salivary Glands in CP
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who have swallowing disorders, posterior drooling may 
cause coughing, nausea, vomiting, aspiration into the 
airway, and if severe, aspiration pneumonia.
5
  Many studies have investigated the clinical improvement 
in drooling after the injection of botulinum toxin type 
A (BTXA). In one study, BTXA was injected into rat 
salivary glands and the resulting change in structure 
and function was monitored.
6 Another study reported 
salivary gland shrinkage following the injection of BTXA 
into rat salivary glands.
7 However, there has been no 
research studying human subjects. Th   is study used neck 
computed tomography (CT) to compare the size of the 
salivary glands before and after BTXA injection, aiming 
to examine morphological changes in the salivary glands 




  From November 2009 to August 2010, eight cerebral 
palsy patients (6-30 years-of-age; mean 17.25±8.26 years; 
five men, three women) presented to our hospital for 
treatment of drooling. Six patients had spastic tetraplegia 
and two patients had spastic hemiplegia. According to 
the Gross Motor Function Classifi  cation System (GMFCS), 
one was rated as level 1 and the remaining seven as level 5. 
Th   ey maintained oral feeding (Table 1).
Methods
  To evaluate the effect of BTXA injection on drooling, 
measurements were done before injection and after 3 
weeks using the Teacher Drooling Scale (TDS; Table 2),
1 
Drooling Score System (DSS)-severity, frequency (Table 
3),
8 and a 0-10 Visual Analogue Scale (VAS; mild - 0 point; 
severe - 10 points). To observe morphological changes in 
the salivary glands, neck CT was done originating from 
Frankfort horizontal plane as a basis, which is known 
to represent the size of salivary glands most accurately, 
to measure the maximum cross-sectional area (MCSA) 
in the parotid gland and the submandibular gland 
before injection and after 3 weeks (Fig. 1). At this time, 
individual glands were measured three times to calculate 
the mean for indicating the size of the salivary glands.
  BTXA Botox
® (Allergan, CA, USA) was injected into the 
both submandibular and parotid glands in each patient 
by ultrasound guidance (1 unit/gland/kg: maximum 100 
units). Th   e procedure was cooperative in three patients, 
who underwent aseptic procedures without anesthesia. 
The remaining patients received an aseptic injection 
under intravenous sedation using midazolam and 
fentanyl citrate. Electrical nerve stimulation was used for 
injection into the parotid glands to confirm that it was 
not a facial nerve. SPSS 12.0 version for Windows (SPSS, 
Chicago,  USA) was used for statistical analysis; VAS, TDS, 
Table 1. Characteristics of the Children with Cerebral 
Palsy
Subject Age/Sex Diagnosis GMFCS
Weight
(kg)
1   6/M Left hemiplegia 1 13
2 11/F Quadriplegia 5 20
3 14/M Quadriplegia 5 26
4 11/M Quadriplegia 5 23
5 30/M Right hemiplegia 5 60
6 22/F Quadriplegia 5 42
7 18/M Quadriplegia 5 49
8 26/F Quadriplegia 5 26
GMFCS: Gross motor function classifi  cation system
Table 2. Degrees of the Teacher Drooling Scale
Degree Description
1 No drooling
2 Infrequent drooling, small amount
3 Occasional drooling, intermittent all day
4 Frequent drooling, but not profuse
5 Constant drooling, always wet
Table 3. Degrees of the Drooling Scoring System
Severity Frequency
Degree Description
1 Dry (never drools) Never
2 Mild (only lips well) Occasionally (not
 every day)




4 Severe (drool extends
 to wet clothes)
Constantly
5 Profuse (drool extends
 to wet hands, tray,
 objects)Zee-Ihn Lee, et al.
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DSS, and Wilcoxon signed rank test were used to compare 
the size of salivary glands before and after injection. Th  e 
results are presented as median and range (min and 
max), with a p-value of 0.05 indicating signifi  cance. Th  is 
study was approved by the Institutional Review Board of 
Dae-gu Fatima Hospital. 
RESULTS
Changes in VAS, TDS, DSS-severity and frequency 
  Statistically signifi  cant improvements in drooling were 
shown in all four parameters; from VAS 7.00 (6-8) to 4.00 
(2-7), TDS 4.50 (3-5) to 3.00 (2-3), DSS-severity 4.00 (3-
5) to 3.00 (2-3), and frequency 4.00 (2-4) to 2.00 (1-3) 
(p<0.05) (Table 4).
Change in size of salivary glands
  Th   e mean MCSA was statistically signifi  cantly reduced 
after 3 weeks from 3.19 (2.77-4.10) cm
2 to 2.76 (2.18-4.11) 
cm
2 in the right submandibular glands; 2.98 (2.38-4.10) 
cm
2 to 2.76 (2.28-3.51) cm
2 in the left submandibular 
glands; 5.47 (3.23-9.84) cm
2 to 4.74 (2.6-7.0) cm
2 in the 
right parotid glands; and 5.18 (2.99-9.56) cm
2 to 4.39 (2.8-
7.0) cm
2 in the left parotid glands (p<0.05) (Table 5).
DISCUSSION
  Tahmassebi and Curzon
10 studied people in special-
education schools and reported that 58% of children 
with cerebral palsy displayed drooling and 33% of them 
displayed severe drooling. Ekedahl
11 demonstrated that 
about 10% of children with cerebral palsy have severe 
drooling. In Korea, Park et al.
12 performed a survey on 
drooling in children with cerebral palsy, reporting that 
about 23% of them presented with drooling and 84% 
with severe drooling for which their parents desired 
correc    tive treatment. Among the many treatment 
methods developed for drooling, anti-cholinergic 
agents such as benzotropine, glycopyyrolate, and 
bezhexol hydrochloride are effective. However, these 
agents can produce various adverse events such as 
orthostatic hypotension, bradycardia, urinary reten-
tion, constipation, and diarrhea.
13 Drooling can also 
Table 4. Comparison of Pre-/Post- Botulinum Toxin 
Type A Injection into the Salivary Glands
Pre After 3 wks
VAS 7.00 (6-8) 4.00 (2-7)*
TDS 4.50 (3-5) 3.00 (2-3)*
DSS-severity 4.00 (3-5) 3.00 (2-3)*
DSS-Frequency 4.00 (2-4) 2.00 (1-3)*
Values are median (range)
VAS: Visual analog scale, TDS: Teacher drooling scale, 
DSS: Drooling scoring system
*p<0.05








3.19 (2.77-4.10) 2.76 (2.18-4.11)*
Rt.parotid gland 5.47 (3.23-9.84) 4.74 (2.6-7.0)*
Lt.submandibular
 gland
2.98 (2.38-4.10) 2.76 (2.28-3.51)*
Lt.parotid gland 5.18 (2.99-9.56) 4.39 (2.8-7.0)*
Values are median (range)
MCSA: Maximum cross-sectional area
*p<0.05
Fig. 1. Representative CT of salivary 
glands. Outline of salivary glands 
were drawn with yellow lines on 
this CT. CT was three millimeter 
contiguous axial scans and parallel 
to the Frankfort horizontal plane. (A), 
parotid gland; (B), submandibular 
gland.Eﬀ  ect of BTXA on  Morphology of Salivary Glands in CP
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be surgically treated by the changing direction of 
the secretory duct of parotid glands and removing 
the salivary glands. However, this might bring about 
complications such as dysphagia, airway stenosis, and 
xerostomia.
14,15 Since the 1997 report that drooling is 
improved by BTXA injection into the salivary glands in 
patients with amyotrophic lateral sclerosis,
16 injection 
of BTXA into the salivary glands in patients with brain 
injury including cerebral palsy has been attempted. Th  e 
collective results have led to the view that BTXA injection 
is an eff  ective treatment for improving drooling without 
signifi  cant adverse events compared to existing methods 
such as the use of anti-cholinergic agents or surgery.
17-19 
  Salivary secretion is regulated by the autonomic nervous 
system; the sympathetic system primarily controls 
composition of saliva while the parasympathetic system 
regulates the secretion amount. As acetylcholine is 
secreted at the terminals of parasympathetic nerve fi  bers, 
saliva is produced.
20 When BTXA reaches the target 
tissue, it is internalized via endocytosis into the nerve 
cells at the axon terminal, where it binds to the soluble 
N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) protein complex, which contributes to 
release of acetylcholine, resulting in proteolytic cleavage 
of the SNARE protein complex. It is assumed, but as yet 
unproven, that BTXA reduces drooling by suppressing the 
secretion of acetylcholine in the neuroglandular junction, 
the terminal of parasympathetic nerve fi  bers.
21,22
  Coskun et al.
7 injected BTXA into the submandibular 
glands of 15 rats, 4 to 6-month-old rats and observed 
morpho  logical changes using ultrasound. Shrinkage 
of salivary glands were observed at 2 and 4 weeks after 
injection. However, there was no particular change other 
than lymphocyte infiltration in histologic examination. 
On the other hand, Teymoortash et al.
6 injected BTXA 
and saline into rat submandibular glands and examined 
morphological change through histologic examination, 
and observed shrinkage of glandular cells, decreased 
size of acinar cells, and reduced granules in acinar cells. 
It is assumed that the action of SNARE protein complex 
is controlled by BTXA, causing denervation due to 
suppressed release of acetylcholine in the neuroglandular 
junction, resulting in decreased secretion of granules 
from acinar cells. To date, studies have attempted to 
clarify the  action mechanism of BTXA, which reduces 
drooling, in the salivary glands of animals. However, 
little is known concerning human subjects. This study 
used CT to identify clinical improvement in drooling and 
morphological changes in the salivary glands after BTXA 
injection. According to Heo et al.,
9 neck CT originating 
from Frankfort horizontal plane as a basis most accurately 
represent the size of salivary glands. Thus, CT was used 
to measure and compare the mean size of salivary 
glands before injection and after 3 weeks based on the 
method above, confirming the clinical improvement in 
drooling and signifi  cant reduction of salivary gland size 
after 3 weeks of injection. Our results with cerebral palsy 
patients echo those of Coskun et al.
7, who suggested that 
BTXA injection in patients with cerebral palsy leads to 
shrinkage of salivary glands and it might contribute to 
clinical improvement in drooping. Th   e present result may 
corroborate the suggestion of Jongerius et al.
1 that the 
BTXA eff  ect lasts longer by repeated injection in patients 
with cerebral palsy because of salivary glands shrunk due 
to denervation. 
  However, in this study, there were few subjects and no 
histologic examination was performed so that it could 
not observe any histologic change in salivary gland cells 
after injection. It might be helpful to demonstrate the 
action mechanism of BTXA in the salivary glands by long-
term follow-up for BTXA injection and changes in the 
size of salivary glands with more patients, or additional 
research on correlation between the degree of shrinkage 




  BTXA was injected into the salivary glands in patients 
with cerebral palsy having severe drooling, demonstrating 
clinical improvement in drooling. CT performed before 
injection and after 3 weeks was done to show the action 
mechanism of BTXA in the salivary glands, resulting in 
significant reduction in its size. Therefore, it is thought 
that shrinkage of salivary glands might contribute to 
improvement of drooling.
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